MX2009003417A - Metodo de inmunizacion contra los 4 serotipos de dengue. - Google Patents

Metodo de inmunizacion contra los 4 serotipos de dengue.

Info

Publication number
MX2009003417A
MX2009003417A MX2009003417A MX2009003417A MX2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A MX 2009003417 A MX2009003417 A MX 2009003417A
Authority
MX
Mexico
Prior art keywords
dengue
serotype
dose
series
dengue serotypes
Prior art date
Application number
MX2009003417A
Other languages
English (en)
Spanish (es)
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2009003417A publication Critical patent/MX2009003417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009003417A 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue. MX2009003417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (1)

Publication Number Publication Date
MX2009003417A true MX2009003417A (es) 2009-04-09

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003417A MX2009003417A (es) 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue.

Country Status (15)

Country Link
US (2) US7718358B2 (enExample)
EP (3) EP2526965A1 (enExample)
JP (1) JP5269796B2 (enExample)
KR (1) KR20090064593A (enExample)
CN (2) CN101553251B (enExample)
AR (1) AR063057A1 (enExample)
AU (1) AU2007311792B2 (enExample)
BR (1) BRPI0719849A2 (enExample)
CA (1) CA2663885A1 (enExample)
FR (1) FR2906724B1 (enExample)
IL (2) IL197768A0 (enExample)
MX (1) MX2009003417A (enExample)
TW (2) TWI406673B (enExample)
WO (1) WO2008047023A2 (enExample)
ZA (1) ZA200901816B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10238734B2 (en) * 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
SG195115A1 (en) * 2011-06-29 2013-12-30 Immunotope Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
EP2858668A1 (en) * 2012-06-10 2015-04-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
JP2015524421A (ja) * 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
WO2014204892A1 (en) 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
TWI736563B (zh) * 2015-11-27 2021-08-21 日商Ｋｍ生物醫藥股份有限公司 庫存之登革熱病毒減毒株的活病毒及以此等做為抗原之登革熱疫苗
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
KR20220049023A (ko) 2019-08-16 2022-04-20 다케다 백신즈 인코포레이티드 뎅기열 및 a형 간염을 예방하기 위한 방법
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
DE69830579T2 (de) 1997-02-28 2006-05-04 Acambis, Inc., Cambridge Chimäre impfstoffe gegen flaviviren
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
AU4040400A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
US6528065B1 (en) 1999-03-26 2003-03-04 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-3 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
ES2533085T3 (es) 2001-05-22 2015-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
JP2005518332A (ja) 2001-05-23 2005-06-23 デンドレオン コーポレイション 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
AU2002322026B2 (en) 2001-06-01 2008-03-13 Acambis Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US7459160B2 (en) * 2002-01-15 2008-12-02 Acambis Inc. Chimeric flaviviruses
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
CN1791433B (zh) * 2003-03-24 2010-05-26 斯克里普斯研究学院 抗肿瘤生长的dna疫苗及其使用方法
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
US20100270202A1 (en) 2010-10-28
AU2007311792B2 (en) 2013-05-02
JP5269796B2 (ja) 2013-08-21
AU2007311792A1 (en) 2008-04-24
ZA200901816B (en) 2010-06-30
US7718358B2 (en) 2010-05-18
EP2526964A1 (fr) 2012-11-28
EP2077857B1 (fr) 2013-11-20
FR2906724B1 (fr) 2009-03-20
CN103285386A (zh) 2013-09-11
CA2663885A1 (en) 2008-04-24
WO2008047023A2 (fr) 2008-04-24
JP2010505801A (ja) 2010-02-25
US20080085288A1 (en) 2008-04-10
TW201336508A (zh) 2013-09-16
AR063057A1 (es) 2008-12-23
TWI406673B (zh) 2013-09-01
EP2077857A2 (fr) 2009-07-15
FR2906724A1 (fr) 2008-04-11
IL197768A0 (en) 2011-08-01
KR20090064593A (ko) 2009-06-19
WO2008047023A3 (fr) 2008-10-23
CN101553251A (zh) 2009-10-07
EP2526965A1 (fr) 2012-11-28
CN101553251B (zh) 2013-05-22
BRPI0719849A2 (pt) 2014-04-29
TW200826959A (en) 2008-07-01
IL224572A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
MX2009003417A (es) Metodo de inmunizacion contra los 4 serotipos de dengue.
MY169275A (en) Method of immunization against the four serotypes of dengue
MY180698A (en) Immunization protocol against the 4 dengue serotypes
NO20072733L (no) Doseformer
TW200612987A (en) Combination treatment for non-hematologic malignancies
WO2007131168A3 (en) Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
NO20091954L (no) Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX2009011867A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
FI3757126T3 (fi) Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
MX2010003556A (es) Regimen de tratamiento para trastornos proliferantes.
JP2007508326A5 (enExample)
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea
MY153290A (en) Multivalent avian influenza vaccines
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.

Legal Events

Date Code Title Description
FG Grant or registration